Please login to the form below

Not currently logged in
Email:
Password:

CDK4/6 inhibitor

This page shows the latest CDK4/6 inhibitor news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Sanofi’s all-oral sleeping sickness drug

CHMP backs Sanofi’s all-oral sleeping sickness drug

Among these, Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) was recommended for the treatment of women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant

Latest news

  • Novartis claims a rare win at ESMO for PI3K inhibitor class Novartis claims a rare win at ESMO for PI3K inhibitor class

    16%. Alpelisib was also fairly well tolerated in the 572-patient study, which involved patients whose disease had progressed after earlier treatment with an aromatase inhibitor with or without a ... 6 inhibitor, a newer drug group which includes

  • Lilly gets EMA nod for Verzenio in breast cancer Lilly gets EMA nod for Verzenio in breast cancer

    Eli Lilly has the approval it was looking for in Europe for CDK4/6 inhibitor Verzenio, allowing to challenge rivals from Pfizer and Novartis in breast cancer. ... women. It’s not all been plain sailing for Lilly’s CDK4/6 inhibitor programme however.

  • Novartis considers filings for PI3K drug in breast cancer Novartis considers filings for PI3K drug in breast cancer

    Novartis has positive phase III results in hand for its PI3K inhibitor alpelisib in advanced breast cancer patients, which it hopes will be enough to file for regulatory approvals. ... The two regimens were compared in patients whose cancer had

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    It also backed three targeted cancer drugs: Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) as a combination for BRAF V600-positive melanoma; and Eli Lilly’s ... CDK4/6 inhibitor Verzenios (abemaciclib)

  • FDA backs earlier use of Lilly’s breast cancer drug Verzenio FDA backs earlier use of Lilly’s breast cancer drug Verzenio

    Eli Lilly has picked up yet another FDA approval for CDK4/6 inhibitor Verzenio - its third in five months - as it tries to chase down Pfizer’s category-leading Ibrance. ... year and is predicted to become a $6bn product at peak by EvaluatePharma - as

More from news
Approximately 2 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics